Platinum-based anticancer drugs, including cisplatin, carboplatin, oxaliplatin, nedaplatin,
and lobaplatin, are heavily applied in chemotherapy regimens. However, the intrinsic or …

The organic cation transporters (OCTs) OCT1, OCT2, OCT3, novel OCT (OCTN) 1, OCTN2,
multidrug and toxin exclusion (MATE) 1, and MATE kidney-specific 2 are polyspecific …

Transporters influence the disposition of chemicals within the body by participating in
absorption, distribution, and elimination. Transporters of the solute carrier family (SLC) …

Transporters in proximal renal tubules contribute to the disposition of numerous drugs.
Furthermore, the molecular mechanisms of tubular secretion have been progressively …

Medications are a common cause of AKI, especially for patients admitted to hospital wards
and the intensive care unit. Although drug-related kidney injury occurs through different …

The use of the effective antineoplastic agent cisplatin is limited by its serious side effects,
such as oto-and nephrotoxicity. Ototoxicity is a problem of special importance in children …

Oxaliplatin was the third Pt-based anticancer drug to be clinically used worldwide. It exhibits
a broad spectrum of anticancer activity and was the first to be approved for the treatment of …

Cisplatin is one of the most widely used anticancer agents for the treatment of solid tumors.
The clinical use of cisplatin is associated with dose‐limiting nephrotoxicity, which occurs in …

In vitro screens for nephrotoxicity are currently poorly predictive of toxicity in humans.
Although the functional proteins that are expressed by nephron tubules and mediate drug …

Nanoparticle formulations for packaging existing drugs have been used to treat cancer.
Lipoplatin™ is a liposomal cisplatin encapsulated into liposome nanoparticles of an average …